Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
Director departure
Appointed director
Quarterly results
CC transcript
MEDIVATION, INC. (MDVN) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2016 8-K Quarterly results
09/02/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/22/2016 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Departure of Directors or C...
Docs: "Agreement and Plan of Merger, by and among Medivation, Inc., Pfizer Inc. and Montreal, Inc",
"Amendment No. 1 to Rights Agreement, by and between Medivation, Inc. and American Stock Transfer & Trust Company, LLC",
"PFIZER TO ACQUIRE MEDIVATION"
07/29/2016 8-K Form 8-K - Current report
07/06/2016 8-K Investor presentation
Docs: "Investor presentation titled “Talazoparib (MDV3800): A Potentially Best-in-Class PARP Inhibitor”"
07/05/2016 8-K Form 8-K - Current report
06/27/2016 8-K Form 8-K - Current report
06/24/2016 8-K Form 8-K - Current report
06/23/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Medivation Sends Letter to Stockholders to Set the Record Straight on Sanofi's Misleading Claims",
"Letter to Medivation employees sent on June 23, 2016"
06/13/2016 8-K Form 8-K - Current report
06/03/2016 8-K Investor presentation
Docs: "Investor presentation titled “Delivering Value Now and Into the Future”"
06/01/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "MEDIVATION SETS RECORD DATE FOR SANOFI'S PROPOSED CONSENT SOLICITATION SAN FRANCISCO, CA - June 1, 2016 - Medivation, Inc. today confirmed that it has received a request from Sanofi to establish a record date to determine which of the Company's stockholders are eligible to participate in the proposed solicitation of written consents by Sanofi . In accordance with that request, the Company's Board of Directors has set the close of business on June 1, 2016 as the record date for the Sanofi Consent Solicitation. The solicitation of consent forms is not permitted prior to the clearance of solicitation materials by the Securities and Exchange Commission. Following SEC clearance of Sanofi's consent solicitation statement, Medivation stockholders of record as of June 1, 2016 are eligible to submi...",
"Letter to Medivation employees sent on June 1, 2016"
05/27/2016 8-K Form 8-K - Current report
05/25/2016 8-K Form 8-K - Current report
05/16/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Communication to certain Medivation managers sent on May 16, 2016"
05/11/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Transcript from the Company presentation at the BAML Healthcare Conference on May 11, 2016"
05/09/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Investor presentation titled “Delivering Value Now and Into The Future.”"
05/06/2016 8-K Form 8-K - Current report
05/05/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Investor presentation relating to Medivation's first quarter ended March 31, 2016, financial results and corporate update",
"Investor presentation titled “Medivation Business Performance and Future Prospects: Delivering Value Now and Into The Future.”"
05/05/2016 8-K Form 8-K - Current report
04/29/2016 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Amended and Restated Bylaws of Medivation, Inc"
04/29/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "MEDIVATION'S BOARD OF DIRECTORS UNANIMOUSLY REJECTS SANOFI'S UNSOLICITED PROPOSAL",
"Letter to Medivation employees sent on April 29, 2016"
04/28/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "MEDIVATION CONFIRMS RECEIPT OF UNSOLICITED PROPOSAL FROM SANOFI SAN FRANCISCO, CA - April 28, 2016 - Medivation, Inc. confirmed today that it has received an unsolicited, non-binding proposal from Sanofi to acquire all outstanding shares of Medivation common stock for $52.50 in cash. On April 15, 2016, Medivation's Board of Directors received a private letter from Sanofi making an indicative, non-binding proposal to acquire the Company under the same economic terms, subject to completion of due diligence and other conditions. The Company promptly acknowledged receipt of the letter and committed to respond. Consistent with its fiduciary duties, the Board, with the assistance of its independent financial and legal advisors, immediately began the process of evaluating this proposal. As today..."
04/08/2016 8-K/A Form 8-K/A - Current report [Amend]
03/28/2016 8-K Form 8-K - Current report
03/10/2016 8-K/A Form 8-K/A - Current report [Amend]
03/09/2016 8-K Form 8-K - Current report
02/25/2016 8-K Quarterly results
Docs: "MEDIVATION REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS AND PROVIDES 2016 FINANCIAL GUIDANCE"
02/23/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/29/2016 8-K Regulation FD Disclosure
01/25/2016 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Updated corporate presentation"
01/11/2016 8-K Investor presentation
Docs: "Presentation slides"
12/18/2015 8-K/A Financial Statements and Exhibits
Docs: "Consent of Independent Auditors",
"Audited financial statements of the talazoparib research program as of December 31, 2014 and 2013, and the results of operations and cash flows for each of the two years in the period ended December 31, 2014, and related notes to such audited financial statements",
"Unaudited financial statements of the talazoparib research program as of September 30, 2015 and December 31, 2014, and the related unaudited statements of operations and cash flows for the nine months ended September 30, 2015 and 2014, and the related notes to such unaudited financial statements",
"Unaudited pro forma condensed combined financial statements as of September 30, 2015, for the nine month period ended September 30, 2015, and for the year ended December 31, 2014, and the related notes to such unaudited financial statements"
12/07/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy